Modality
ADC
MOA
EZH2i
Target
Aβ
Pathway
Hedgehog
FTDPNH
Development Pipeline
Preclinical
~Jun 2022
→ ~Sep 2023
Phase 1
Dec 2023
→ Sep 2031
Phase 1Current
NCT07160008
1,527 pts·PNH
2023-12→2031-09·Recruiting
1,527 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-045.4y awayInterim· PNH
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2031-09-04 · 5.4y away
PNH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07160008 | Phase 1 | PNH | Recruiting | 1527 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ |